TLDR
- Clorox shares plummeted to a 52-week low of $88.38, declining 27.25% year-over-year
- The company reported Q3 FY2026 earnings per share of $1.64, surpassing expectations by $0.10
- Full-year net sales are now projected to decline approximately 6% for fiscal 2026
- Major Wall Street firms including Goldman Sachs, Morgan Stanley, UBS, and Evercore ISI lowered price targets
- Analysts express caution despite the quarterly earnings outperformance
Shares of Clorox (CLX) plunged to a 52-week low on May 1, first touching $91.00 before continuing to slide to $88.38. The consumer goods giant has now lost 27.25% of its value over the trailing twelve months.
The steep decline followed the company’s April 30 release of third-quarter fiscal 2026 results and a significant reduction in its full-year projections.
At first glance, the quarterly performance appeared solid. The company delivered non-GAAP earnings per share of $1.64, exceeding Wall Street’s consensus estimate of $1.55 by ten cents. Quarterly revenue reached $1.67 billion, meeting analyst expectations.
However, the forward-looking guidance painted a considerably bleaker picture. The household products manufacturer now anticipates net sales will contract by approximately 6% for the full fiscal year 2026—a significant deterioration from previous projections.
The company also lowered its adjusted earnings per share forecast for the fiscal year to a range of $5.45 to $5.65, down substantially from the earlier guidance of $5.95 to $6.30.
Shares declined roughly 2% in the immediate aftermath of the earnings announcement.
Wall Street Analysts Slash Price Targets
The downgraded outlook prompted swift reactions from Wall Street’s leading investment banks.
Goldman Sachs reduced its price target to $83 from $94, explicitly referencing the weakened guidance as the primary rationale for the adjustment.
UBS lowered its price objective to $96 from $110 while maintaining its Neutral stance on the stock. Morgan Stanley similarly cut its target to $97 from $110, highlighting ongoing sales pressures across specific product lines.
Evercore ISI adjusted its target downward to $110 from $115, noting that third-quarter results benefited from the elimination of royalty payments related to Glad products—a non-recurring advantage that won’t continue.
Fundamental Analysis Reveals Challenges
Clorox currently trades at a price-to-earnings multiple of 15.76x, which certain analysts consider reasonable relative to current earnings power. According to InvestingPro analysis, the stock appears undervalued at present price levels.
The company’s GF Score stands at 68 out of 100. While profitability metrics earn a respectable 7/10 rating, growth scores merely 1/10—a significant red flag in the competitive consumer packaged goods sector.
Financial strength receives a middling 4/10 rating, suggesting potential vulnerabilities in debt management and cash generation capabilities.
Management indicated that the recently completed GOJO acquisition should provide some offset to the revenue headwinds, though the overall sentiment remains decidedly cautious.
Insider transaction activity has been minimal over the past year—two purchases and one sale, with the divestiture totaling approximately $1.86 million.
The company’s market capitalization now stands at roughly $11.66 billion, representing a substantial erosion from its valuation twelve months ago.
The new 52-week low of $88.38 marks the latest milestone in a prolonged downtrend that has persisted throughout the current fiscal year.
